Belatacept instead of tacrolimus for early kidney graft problems
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) and had a kidney transplant from a living or deceased donor.
- Your blood types match in an allowed way for transplant (ABO-compatible) and the donor is not an exact HLA match.
- Your kidney function is reduced (creatinine clearance under 30 ml/min/1.73m²) based on the CKD-EPI estimate.
- Your 10-week post-transplant biopsy must show no rejection and no BK virus–related kidney damage, and no certain other damage problems.
- You must be Epstein-Barr virus (EBV) positive, and you must not have HIV.
- You must currently take CNI plus mycophenolate (MPA) with or without prednisone, and you must be able to understand and follow study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
Hear when a new Chronic Kidney Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.